{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-23-001476","form_type":"8-K","ticker":"DRMA","cik":"0001853816","company_name":"Dermata Therapeutics, Inc.","filed_at":"2023-02-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.169863+00:00","generated_at":"2026-06-19T22:01:51.010633+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Dermata shareholders approve reverse stock split with ratio up to 1:40","bullets":["Reverse stock split proposal approved: 7,622,928 for, 135,481 against.","Board authorized to set ratio between 1:2 and 1:40, exact ratio to be determined later.","Adjournment proposal also approved with 7,681,932 votes for.","Special meeting held Feb 8, 2023; vote based on 12,321,848 shares outstanding."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-23-001476","json":"https://secwatch.observer/filing/0001654954-23-001476.json","markdown":"https://secwatch.observer/filing/0001654954-23-001476.md","text":"https://secwatch.observer/filing/0001654954-23-001476.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1853816/000165495423001476/0001654954-23-001476-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1853816/000165495423001476/drma_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T22:01:51.010633+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"189e7d66dc50dedc82d1c0c28325ac66e0382811","claim":"Dermata Therapeutics, Inc. shareholders approved Approval of the adjournment of the special meeting to the extent there are insufficient votes to approve the reverse stock split proposal at the 2023-02-08 meeting.","evidence_excerpt":"Proposal No. 2 : The Adjournment Proposal was approved by a vote of stockholders as follows: Votes For Votes Against Abstentions 7,681,932 87,554 28,592","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1853816/000165495423001476/0001654954-23-001476-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"reverse split"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-02-08"}],"fact_type":"shareholder_vote"},{"claim_id":"4875c626dc3f78d9757c144577841a27fb52502f","claim":"Dermata Therapeutics, Inc. shareholders approved Adoption and approval of an amendment to the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock split at a ratio from one-for-two to one-for-forty, with the exact ratio determined by the board at the 2023-02-08 meeting.","evidence_excerpt":"Proposal No. 1 : The Reverse Stock Split Proposal was approved by a vote of stockholders as follows: Votes For Votes Against Abstentions 7,622,928 135,481 39,669","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1853816/000165495423001476/0001654954-23-001476-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"reverse split"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-02-08"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}